Semiconductor diode laser photocoagulation in retinal vascular disease

Area of Science:

• Ophthalmology
• Medical Technology
• Laser Medicine

Background:

• Retinal vascular diseases necessitate effective therapeutic interventions.
• Transpupillary retinal photocoagulation is a key treatment modality.
• Evaluating novel laser technologies for retinal applications is crucial.

Purpose of the Study:

• To assess the clinical efficacy and safety of a gallium-aluminium-arsenide (GaAlAs) diode laser for transpupillary retinal photocoagulation.
• To compare the energy requirements and lesion characteristics of the GaAlAs diode laser with the argon green laser.
• To evaluate patient-reported pain and intraoperative complications associated with diode laser treatment.

Main Methods:

• Clinical transpupillary retinal photocoagulation performed in 30 eyes of 26 patients with retinal vascular disease.
• Utilized a GaAlAs diode laser (805 nm) with specific power, duration, and spot size parameters.
• Comparative analysis of laser energy and power requirements against argon green laser in patients and Chinchilla rabbits.

Main Results:

• The GaAlAs diode laser successfully achieved therapeutic retinal photocoagulation.
• Diode laser required significantly more energy (4.5x) than argon green laser for similar lesions in patients.
• Experimental studies showed diode laser needed more power (3.1x) than argon laser in rabbits.
• Intraoperative subretinal hemorrhage was rare (0.44% incidence).
• Moderate-to-marked pain reported in 43% of treatments under topical anesthesia.

Conclusions:

• Transpupillary retinal photocoagulation using a GaAlAs diode laser is clinically feasible for retinal vascular diseases.
• The diode laser may serve as an alternative to argon green lasers, though with higher energy demands.
• Further investigation into pain management and optimal parameters for diode laser retinal photocoagulation is warranted.